Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Review Cost For Sanofi/Regeneron’s PCSK9 Inhibitor Remains Uncertain

This article was originally published in The Pink Sheet Daily

Executive Summary

Even after paying BioMarin $67.5 million for the voucher itself, the firms still don’t know how much FDA will charge for a chance to get Praluent to market faster.

You may also be interested in...



Pediatric Vouchers Can Have Heavy Adult Involvement, FDA Says

Draft guidance says sponsors remain eligible for rare pediatric disease priority review voucher even if they enroll also adults in clinical trials.

FDA Priority Review Costs Remain Stable While Voucher Fee Ticks Up

Formula was changed to better calculate the cost of a priority review, FDA says.

How Much Is A Priority Review Worth? $67.5 Million, Sanofi/Regeneron Say

Companies’ decision to purchase and redeem BioMarin’s priority review voucher for their PCSK9 inhibitor alirocumab sets the first public benchmark for a voucher’s value and shows the potential advantages to be gained for sponsors in a race to market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel